Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer

Inclusion Criteria:

• Written informed consent for all study procedures according to local regulatoryrequirements prior to beginning specific protocol procedures

• Female patients

• Age 18-74 years

• ECOG Performance Status of 0 or 1

• Histologically confirmed, untreated, invasive breast carcinoma stage II-IIIB

• Tumor size > 2 cm by clinical or radiological assessment

• HER2+ invasive BC according to ASCO/CAP guidelines

• Known hormone receptor status or the possibility of its assessment

• Adequate organ function defined as:

• Absolute Neutrophil Count (ANC) ≥ 1.5 x 10**9/L

• Hemoglobin (Hgb) ≥ 9 g/dL

• Platelets > 100 x 10**9/L

• Creatinine ≤ 1.6 mg/dL

• ALT and AST ≤ 2.5 x ULN

• Alkaline phosphatase ≤ 5 ULN

• Total bilirubin ≤ 1.5 mg/dL

• Baseline LVEF ≥ 55% measured by echocardiogram or MUGA scan

• Negative β-HCG pregnancy test (serum) for premenopausal women of reproductive capacity (those who are biologically capable of having children) and for women less than 12months after the menopause. All subjects who are biologically capable of havingchildren must agree and commit to the use of a reliable method of birth control from 2weeks before administration of the first dose of investigational product until 28 daysafter the last dose of investigational product

• Absence of any psychological, familial, sociological, or geographical conditionpotentially hampering compliance with the study protocol and follow-up schedule; thoseconditions should be discussed with the patient before registration in the trial

Exclusion Criteria:

• Clinical or radiologic evidence of metastatic disease at the time of study entry

• Prior chemotherapy, radiotherapy, or surgery for BC, other than excision of a tumor inthe contralateral breast, and provided that the patient did not previously receiveadjuvant radiotherapy or chemotherapy

• Subjects with a concurrently active second malignancy, other than adequately treatednon melanoma skin cancers, in situ melanoma or in situ cervical cancer. Subjects withother non-mammary malignancies must have been disease-free for at least 5 years

• Known or suspected hypersensitivity reaction to any investigational or therapeuticcompound or their incorporated substances

• Presence of CHF or LVEF < 55%

• Clinically significant (i.e. active) cardiovascular disease, including cerebrovascularaccident (< 6 months before enrollment), unstable angina pectoris, myocardialinfarction ≤ 6 months before enrollment, uncontrolled hypertension (systolic > 150mmHg and/or diastolic > 100 mmHg), or high-risk uncontrolled arrhythmias

• Uncontrolled diabetes mellitus, active peptic ulcer disease, or uncontrolled epilepsy

• Active uncontrolled infection at the time of enrolment

• History of significant co-morbidities that, in the judgment of the investigator, mayinterfere with the conduction of the study, the evaluation of response, or withinformed consent

• Use of any investigational agent or participation in another therapeutic clinicaltrial concurrently or in the previous 30 days before the enrollment

• Patients who are pregnant or breast-feeding

• Women of child-bearing potential who are unable or unwilling to use acceptablecontraceptive measures

• Inability or unwillingness to abide by the study protocol or cooperate fully with theinvestigator or designee